Aslan, which develops treatments for tumours prevalent in Asian patients, has secured funding from investors including Accuron and Tianda.
Singapore-based biotechnology company Aslan Pharmaceuticals raised $34m in series C capital yesterday from a consortium led by technology and engineering company Accuron that included drug developer Tianda Pharmaceuticals.
The round also featured securities firm Haitong International, Morningside Ventures, Bioveda Capital, Cenova Ventures and Sagamore Bioventures.
Aslan is working on immunotherapies for tumours that particularly affect patients in Asia. The company currently has four candidates in its pipeline for gastric and breast cancers, and inflammatory diseases.
The funding will help Aslan…
